Jobs
View more job listings or post a job
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
University of California, Davis TOXICOLOGY ANALYTICAL CHEMIST (STAFF RESEARCH ASSOCIATE 3)
University of California, Davis CALIFORNIA ANIMAL HEALTH AND FOOD SAFETY LABORATORY - TOXICOLOGY LAB RESEARCH SUPERVISOR/GROUP LEADER
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Applied BioMath Technical Marketing Specialist
Post a job

Seminar luncheon

Alzheimer's Disease: Untangling What We Thought We Knew and Future Precision Diagnostics and Therapeutics


Speakers: John Sninsky, PhD, CSO-CIO, Superfluid Dx
Organizers:
Date: 2024-06-20
Time: 11:15-13:30 Pacific Time
Registration fee: Major Sponsor: $3000; Vendor Show: $695; Regular attendees: Free
Location: Crowne Plaza, Foster City, CA (San Francisco Bay Area)
Major Sponsor:
Vendor show vendors registered to date: (2)Agilent Technologies; HICOMP MicroTech Co. Ltd
Registration: http://www.PBSS.org
Registration deadline:2024-06-19  (it will close sooner if the seating cap is reached)

About the Topic

Seminar Synopsis: Identifying disease modifying therapies for Alzheimer’s Disease (AD) has proven extremely challenging. The amyloid cascade hypothesis has given way to the ATX (N) conceptual framework. Mild Cognitive Impairment is now recognized as a heterogenous unstable condition that is not a stage in an inexorable progression to AD. Also, we now have evidence that lifestyle interventions can delay progression separate from pharmacotherapies. As with other common complex diseases in the Precision Medicine Era, we need to appreciate that AD is likely a combination of multiple overlapping endotypes with clinical trials and patient management optimally informed by combinations of biomarkers. Through this seminar, the speaker will shed light on the current understanding about the causes of AD, the current state of art in AD  diagnostics and treatment, and the future directions of future precision diagnostics and therapeutics for AD.

 


About the Speakers

John J Sninsky, PhD, is CSO-CIO for Superfluid Dx, an early-stage biotechnology company with a disease agnostic pioneering cell free mRNA platform that uses NGS and machine learning to develop classifiers for compelling unmet clinical needs. Superfluid Dx has prioritized Alzheimer’s Disease. John has a comprehensive and deep understanding of the development and application of pioneering molecular procedures and bioinformatics to the translation of research-grade biomarker assays into clinical-grade clinically adopted diagnostic tests as well as diagnostic tests paired with pharmacotherapies.  John is the author of more than 115 scientific papers including advanced methods in molecular biology and next generation sequencing. He spent 30 years in senior management at companies that ranged from small to enterprise CLIA-CAP laboratories and small to enterprise in vitro diagnostic companies that required FDA clearance and approval for commercialization of kits. He lectures at and advises commercial translation efforts at Stanford University (SPARK) and University of California, San Francisco (CATALYST). John is a Visiting Professor in the Division Infectious Diseases and Vaccinology in School of Public Health at UC Berkeley. He mentors Biomedical Data Science projects for the Data Mine at Purdue University. Through this seminar, the speaker will shed light on the current understanding about the causes of AD, the current state of art in AD diagnostics and treatment, and the future directions of future precision diagnostics and therapeutics for AD.


2024-07-24, [Free Online] The Science and Stories of Promising Biotech Startups: Symposium No.6
2024-08-14, [Free Online] Advances in Cancer Therapeutics
2024-08-22, [Free Online] Diabetes and Obesity Treatments: Current and Emerging Landscapes of GLP-1, GIP, and Beyond
2024-09-10, [In-Person] Translational PK/PD and Human Dose Projections for Antibodies and Novel Therapeutic Modalities: Antibodies, ADCs, Covalent Inhibitors, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
2024-09-20, [In-Person] Nonclinical Safety Assessments of Biologics and Other Novel Modalities for IND/NDA/BLA Filings
2024-09-25, [Free Online] Development of Protein Degraders: Computational Modeling, Medicinal Chemistry and Early Development
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
2024-10-25, [Free Online Workshop] Unleashing the Power of Real-World Evidence / Data (RWE/RWD) to Facilitate Drug Discovery, Development, and Beyond
©Pharmaceutical & BioScience Society, International; Last Modified: 6/15/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Hypha Discovery Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
Lena Biosciences Predictive toxicology. Intrinsic & idiosyncratic drug-induced liver injury. Mitochondrial toxicity in a drug metabolism-competent model.
Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Simulations Plus Join us for MIDD+ San Francisco, a free event June 6-7. Hear scientific presentations from industry leaders, train with experts & connect with peers.
Submit a Text Ad